Takeda Pharma denied general conditional reimbursement in Denmark
The Danish Medicines Agency has rejected Takeda Pharma’s application for general conditional reimbursement for insomnia treatment Slenyto.
by christian bundgaard, translated by daniel pedersen
Takeda Pharma’s insomnia drug Slenyto (melatonin) will not be getting general conditional reimbursement in Denmark, according to a recent decision by the Danish Medicines Agency.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
